logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

RWE and OBA Working Group 2019 Findings & Executive Summary

November 26, 2019
-
Market Access News, Publications
-
Posted by MORSE - < 1 min read.

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available.

 

 

The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

The working group’s 2019 primary focus was on research and analysis to bring clarity on the opportunity for OBAs in Canada, and to develop a framework for OBA implementation in Canada. Please direct any inquiries about this report to info@20sense.ca.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

Share
Tags
CADTH
IHE
OBA
PBRSA
pCODR
pCPA
Reimbursement
Reimbursement strategy
RWD
RWE
← PREVIOUS POST
Summary of the CADTH Drug Portfolio Information Session November 2019
NEXT POST →
The workload at pCPA appears to have stabilized over 2019

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2021 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
RWE and OBA Working Group 2019 Findings & Executive Summary
Private
Public
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB

Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Public
Private
Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB